Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2037 participants.
Also called NCT01950819
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,037 participants
- Sponsor
- Registry
-
NCT01950819 -
2013-000322-66
-
- Other papers using this trial's data
- Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation
- Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study
- Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study
- Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Chile, Colombia, Croatia, Czechia, Egypt, France, Germany, Greece, India, Israel, Italy, Japan, Kuwait, Lebanon, Malaysia, Mexico, Netherlands, Norway, Philippines, Poland, Portugal, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01950819. Randomized; no masking; primary purpose treatment. Start 2013-12-03 (actual); primary completion 2017-02-01 (actual). Results posted on 2019-01-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
- Acronym
- TRANSFORM
- Condition
- End Stage Renal Disease (ESRD)
- Condition
- Hemodialysis
- Condition
- Renal Replacement Therapy
- Condition
- Renal Transplantation
- Intervention (Biological)
- Induction therapy
- Intervention (Drug)
- Corticosteroids
- Intervention (Drug)
- EVR+rCNI
- Intervention (Drug)
- MPA+sCNI
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01950819- Content hash
d3e9459e99db3ffe10e38db568dc2ef5e3f70d3edaa223de46eaeebc4914f835